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Abstract 
 
The goal of this work was to investigate the sources of stigma not only from primary 
literature, but also using a survey conducted at the university of Tennessee-Knoxville. The 
survey also sought to correlate awareness of HIV progression, transmission, and treatment to 
level of stigma. Though there was no overall correlation, the survey did find that fear of 
transmission correlated significantly with overall stigma. The results of the survey aligned with 
other studies performed. The paper goes on to elucidate the way stigma affects people living with 
HIV and their access to medical care, and provides a current outlook on if and how society can 
create a more constructive environment for people living with HIV. 
Introduction 
Human immunodeficiency virus (HIV) has been a hot research topic since its debut in the 
1980s. The retrovirus is excellent at what it does, which is attack the immune cells of its 
unfortunate host so that it can run rampant in the body. Though it has been a prevalent disease 
for over thirty years, the best way of treating HIV remains combined oral antiretroviral 
treatments, which seek to disable viral machinery in a multitude of ways. Current research on 
creating vaccines and cures has told us much about the disease itself, but has not yielded safe 
ways to eradicate the virus. The most common conclusion in HIV research is that the virus is 
more complicated than previously thought. Despite failed attempts at truly novel ways of treating 
HIV, improvements to familiar treatments have been made. But treating HIV is not the only 
challenge surrounding those afflicted. Ever since it reached the public eye, it has been one of the 
most stigmatized diseases of modern times.  
To truly understand current social interaction with people living with HIV (PLHIV), we 
must also understand the history of how HIV came to the forefront as a stigmatized disease. It 
has been established that the virus was transferred to humans in the 1920s or earlier through a 
variant of simian immunodeficiency virus (SIV), most likely due to the consumption of monkey 
in the Kinshasa. By the 1960s, HIV had made its way to Haiti (Faria 2014). When hospitals in 
North America saw the first few cases of HIV in the 80s, they had no way of knowing what they 
were dealing with. They only knew it presented with Kaposi’s sarcoma (KS) and abnormal lung 
infections, and that both were signs of an underlying immune problem. A host of papers 
published by the Centers for Disease Control and Prevention (CDC) in the early 80s showed ever 
increasing symptoms of immunodeficiency in homosexual men, intravenous drug users, and 
blood transfusion recipients. The disease took on many names, such as “gay cancer,” “gay 
compromise syndrome,” and today’s “acquired immunodeficiency syndrome”(Brennan 1981, 
Auerbach 1984, McKay 2014). A 1984 study in the American Journal of Medicine became the 
first of many mapping the spread of HIV based on KS and opportunistic infection in homosexual 
males, concluding that a certain “patient O” had been the source of HIV/AIDS transmission in 
New York, Los Angeles, and San Francisco, among others (Auerbach 1984). Patient zero, as it 
came to be called, was eventually uncovered as Gaetan Dugas, a homosexual Canadian flight 
attendant who was in prime position to carry a sexually transmitted virus from coast to coast 
(Shilts 1987). His symptoms began in 1980, and his continued sexual forays ensured 
transmission across the United States. According to journalist and novelist Randy Shilts, Dugas 
was intent on living a full life despite of his malaise, and despite the consistent warnings from his 
doctors. Two years after his death, his story was published as a part of Shilts’s interpretation of 
the HIV phenomenon, And the Band Played On. The “Patient Zero” story gained enough 
attention to be on 60 Minutes and other news headlines, bolstering the American public’s 
understanding of Dugas and the gay community as the villains behind HIV/AIDS. However, 
Robert McKay opposes this depiction of Dugas in his 2009 article addressing the shortcomings 
of Shilts’s rendition. Shilts used edited interviews to present Dugas as a self-loathing character 
so filled with anger at himself and his condition that he intentionally infected other gay men. At 
the very least, Shilts writes, he was so recklessly intent on carrying out his lifestyle that the 
collateral damage was of little consequence. But, as McKay points out, the CDC only confirmed 
HIV/AIDS as a sexually transmitted virus in April of 1984, one month after Dugas’s death  
(Administration 2014, McKay 2014). Thus, some see Dugas as the antagonist of the HIV/AIDS 
saga, while others count him as an unfortunate victim of a novel virus whose story happened to 
be the most publicized. Whatever the case, Randy Shilts’s book was just part of the highly 
stigmatizing media coverage when HIV/AIDS first became a problem in North America. 
Around the same time Dugas was showing his first symptoms of HIV, the new disease 
was reported to the CDC. However, it was three years before researchers understood the disease 
as a sexually-transmitted virus, and six before the first approved treatment was available. 
Fortunately, the Food and Drug Administration (FDA) had established a faster protocol to get 
treatments approved, started testing blood and plasma stocks, was approving better ways of 
testing for HIV, and approved Retrovir as the first HIV/AIDS treatment by 1987 (Administration 
2014). Despite progress, President Reagan’s response is still criticized today as being too little 
too late. It was not until 1985 that he addressed HIV as an issue, and even then he failed to 
acknowledge that high-risk groups existed outside of the gay community and intravenous drug 
users (Richert 2009).  
Between media coverage and inadequate government reaction, PLHIV were destined for a 
stigmatized existence. The immediate reaction of the U.S. government—silence—represents the 
most dangerous aspect of living with HIV. Worldwide, silence is all too often the primary way 
PLHIV cope with stigma. As one HIV-negative man said of his HIV-positive wife, “I was 
actually safe because I knew her status” (Rispel 2015). Knowledge and disclosure are the keys to 
coexistence with diseases like HIV/AIDS. Not only do these help PLHIV be more comfortable in 
society, but also allow others to better understand the needs that come with living with HIV. In 
this dissertation, the possible connections between awareness of HIV and stigmatizing HIV will 
be explored. How might social stigma borne out of ignorance affect the inclination and ability of 
PLHIV to obtain the necessary resources to manage HIV? And can researchers do more to help 
PLHIV access treatment and live more enjoyable lives? 
Pathogenesis 
What makes HIV such a formidable virus? As a retrovirus, HIV contains two copies of 
single stranded RNA. Upon entering its host, it seeks out CD4+ cells, which include 
macrophages, dendritic cells, and CD4+ T-cells. After gaining access to these cells, viral reverse 
transcriptase can copy the viral ssRNA and convert it to double stranded DNA. The viral DNA 
then enters the host cell’s nucleus and integrates itself into the host genome. This aspect of HIV 
enables it to remain latent for months, even years, before becoming an active virus. Once 
activated, the integrated viral DNA is transcribed into RNA, which is packaged in viral proteins 
produced using the cell’s machinery. From there, new viruses can be released from the host cells 
to continue the viral life cycle (MacPherson 2012). When someone with HIV has a high level of 
viral RNA in his or her blood, he or she is increasingly the subject of opportunistic infection. 
Once that person has a CD4+ count below 200 cells/mm, an HIV infection becomes a case of 
AIDS (CDC 2015). Current treatments are able to rid the body of actively infected cells so that 
the virus is undetectable, but HIV’s ability to integrate complicates completely eradicating the 
virus. Because latent cells can survive for long periods of time, they are a constant source of the 
virus. Since the virus is not active in these cells and established treatments are unable to target 
the machinery that has not been transcribed, it has so far been impossible to truly cure PLHIV in 
all individuals. Even outside of latency, HIV can be highly variable, giving way to resistant 
strains and faster progression of the disease (Acheson 2007). Transmission of the virus is most 
commonly through sex and blood contact, particularly through needle sharing. HIV can also be 
passed through contaminated needle sticks and blood transfusions, or from mother to child 
during childbirth. Contrary to the popular misconception, HIV is not passed through saliva or 
insect vectors, such as mosquitoes (CDC 2015). Transmission is best prevented through 
practicing safe sex and not sharing needles. Adherence to HIV treatments and/or pre-prophylaxis 
treatments (PrEP) also greatly reduces risk of transmission by either keeping the virus at an 
undetectable level or preventing initial infection of the virus. If someone has a high level of 
sexual activity, getting tested annually is recommended (Administration 2014). 
 
Treatments 
One of today’s great challenges of medical research is the ongoing struggle to develop 
the most effective treatments to HIV with the least toxicity and lowest cost. The  most common 
treatment regimens include three different  classes of antiretroviral medications . Because HIV is 
notorious for its rapid mutation, these drugs are used together in a cocktail to avoid a resistant 
viral strain slipping through the cracks. Using a combination of medications as a way of 
managing HIV is called cART (combined antiretroviral therapy) or HAART (highly active 
antiretroviral therapy) (Prevention 2016). 
In the three decades since HIV first surfaced, prevalent treatment options have branched 
out from the FDA’s first treatment approval AZT (azidothymidine) in 1987. Classified as a 
nucleotide reverse transcriptase inhibitor (NRTI), AZT targets an HIV-specific enzyme called 
reverse transcriptase. If the function of the reverse transcriptase can be disrupted, the RNA 
genome contained within the viral capsid cannot be converted to DNA that can be inserted into 
the host cell’s genome. Thus, AZT remains the reference point for most treatments developed . 
More than half of the available treatments for HIV target reverse transcriptase. Though having so 
many versions of medications with similar function may seem redundant, the variety allows 
better treatment plan personalization and higher accessibility. However, using NRTIs  alone has 
proven to be insufficient in cases of viral resistance. The drugs also have a high toxicity and 
therefore several unpleasant side effects (Este 2010). One of the most recent NRTI successes is 
the drug Truvada. It is approved for preexposure prophylaxis, meaning it can prevent HIV from 
truly infecting cells. This has been received as an opportunity for HIV-discordant couples and 
others in high risk groups to greatly reduce their risk of transmission (Prevention 2014). 
Non-nucleotide reverse transcriptase inhibitors (NNRTIs) also target reverse 
transcriptase, but have a different mode of attack. Instead of competing with nucleotide 
substrates that would normally bind to reverse transcriptase as NRTIs do, it attaches to another 
binding site to change to render the active site useless, completely block any kind of binding. 
These have shown fewer side effects due to less interference with host DNA transcription 
machinery (De Clercq 1998). 
 To ameliorate the issues of side effects and resistance, protease inhibitors (PIs) have been 
developed to target a different area of the HIV life cycle. Rather than inhibiting genome 
replication, the viral proteins made as a result of HIV’s successful genome replication are kept 
from being properly cleaved into fully functional proteins by viral proteases. Though not usually 
prescribed as a sole form of treatment, PIs have been shown to be more efficient in controlling 
viral load. While protease inhibitors can lead to viral resistance, the phenomenon is observed less 
often than in NRTIs (Paredes 2010).In addition, PIs are not as effective in crossing the blood-
brain barrier and thus leave room for improvement (Ghosh 2006). Because PIs are effective but 
fall short in reaching as many tissues as NRTIs/NNRTIs, this class of drug is generally used as 
one of three different drugs in cART (Prevention 2016). 
 One of the most recent developments in cART options is the fusion inhibitor. This 
particular drug takes advantage of the fact that, like most viruses, HIV must bind to specific 
receptors on the outside of its targeted immune cells to enter the cell and hijack its machinery. 
By blocking the receptors HIV uses to gain entry, fusion inhibitors prevent the virus from ever 
entering the target cell. With only one fusion inhibitor currently on the market, these types of 
medications are still largely experimental, but are expected to be highly effective for individuals 
with unusually resistant HIV strains. The approach fusion inhibitors take to HIV—a ligand and 
receptor interaction—is favored to lead the field in coming years (Fumakia 2016). 
 Finally, integrase inhibitors (INIs) are another new addition to HIV treatments present a 
new way of attack. These prevent viral DNA from being inserted into the host genome, thereby 
disabling the virus’s ability to create viral proteins and progeny. INIs have a higher efficacy as 
well as a less prevalent association with viral resistance than NRTIs or PIs.  These qualities make 
them prime for people infected with more resistant strains of HIV (Andreoni 2015).  
However, these medications only tell half of the story. They serve as the first stepping 
stones to achieving a functional cure, which serves to keep the virus at undetectable levels in the 
blood without prolonged medication, thereby almost eliminating the transmission risk and 
symptoms of HIVwithout relying on adherence to medication. This strategy is a long term 
treatment which keeps new cells from becoming infected with extant viruses and allowing the 
reservoir to shrink, but not be completely eliminated. Though the current therapies discussed 
thus far can accomplish these undetectable levels of HIV, the therapy is lifelong and quite costly, 
which motivates the research for such a “cure”. The second, more idealistic approach in research 
is complete eradication of the virus from individuals, called a sterilizing cure. While the idea of a 
“total cure” is attractive, the instances in which viruses have been completely removed from the 
body are marginal at best. Simply put, it is not reasonable to expect a single treatment to be 
effective for such a virus.  
 Several avenues for total cures have been explored, focusing on both host and viral 
mechanisms. Gene editing is the basis for many recent attempts because it offers an opportunity 
to not only rid the host’s genome of HIV-derived DNA, but also render the host cell completely 
impermeable to the virus. Removing integrated viral DNA is generally accomplished by using a 
known DNA sequence to create a target for an enzyme to cleave out. The same idea can apply to 
editing the cell before it is ever infected. If the DNA coding for the receptors HIV uses to gain 
access to the cell can be removed, the receptors themselves will never be there for HIV to use. 
Though this option would present a long term or even permanent treatment, actually targeting the 
correct genes without removing other important parts of the host genome has proved difficult 
(Bobbin 2015).  
After cell entry and genomic integration, the next logical mechanism to target is RNA 
synthesis and processing. Ribozymes, or RNA sequences acting as enzymes, can seek out and 
destroy mRNA created as a result of HIV integrating into the host genome. A similar option 
known as RNA interference uses small interfering RNA (siRNA) to target viral RNA sequences 
(Bobbin 2015).  These naturally occurring siRNAs act to silence mRNA so that the protein it 
codes for never comes to fruition. Though siRNA is used in preexisting host mechanisms, siRNA 
can be synthesized to target HIV-related mRNA (Carthew 2009). Another tactic is to create so-
called RNA decoys and RNA aptamers. These bind and therefore debilitate the viral proteins by 
acting as inhibitors. While RNA-based approaches are safer than gene editing and are closer to 
being available to the public, the drawback is that most developed treatments are short term 
(Bobbin 2015). 
 
 
Current Prevalence of Stigma 
Because so little was known about HIV in the eighties, stigma closely followed the fear 
brought on by the mysterious disease. However, PLHIV have yet to escape a stigma created 
decades ago. In a 2015 study on avoidance of PLHIV at a university in the Netherlands, subjects 
were placed in a virtual reality setting in a hospital and were told to memorize chart information 
for patients afflicted with HIV, cancer, or a broken limb. Behavior around each type of patient 
was gauged based on interpersonal space, speed of approaching and leaving patients, and head 
orientation. The virtual patients also varied between homosexual and heterosexual. The study 
found that HIV-positive males were more frequently subjected to avoidance and stigmatizing 
behaviors, such as being kept at farther distances, being stared at more, and having people walk 
away faster than HIV-negative individuals. These behaviors were even more prevalent toward 
homosexual men diagnosed with either cancer or HIV, indicating a generalized stigma toward 
diagnosed homosexual men (Toppenberg 2015). 
Though having these types of studies is useful and necessary, it does not take looking at 
recent peer-reviewed articles to see PLHIV and high risk groups being stigmatized. The most 
recent celebrity to publicly announce a positive serostatus is Charlie Sheen. That he had HIV was 
news in itself, but the fallout of his announcement was incredible. There was hardly a news 
source who did not report about Charlie Sheen’s “former porn star girlfriend” being uninformed 
of his status (Etkin 2015). Why was it worth mentioning that his ex-partner was a sex worker 
before all of the information was available? Was it a covert way of saying he should have seen it 
coming? Other headlines surrounding HIV at the time may not stigmatize HIV directly, but have 
inaccurate information that could promote a flawed understanding of HIV and AIDS. Perhaps the 
worst offender was the ENQUIRER in its article about an unnamed celebrity’s “struggle with 
AIDS,” when the writer was actually referring to a recent positive HIV status. The magazine 
asserted that “decades of debauchery [had] finally caught up with [the celebrity]” (Jessica 2015). 
Another article from ENQUIRER named celebrity Danny Pintauro as being HIV positive, but 
called him “AIDS-stricken” instead (Anonymous 2015). These headlines spread misinformation, 
the stigma already surrounding HIV, and decreased willingness for PLHIV to disclose their 
status and get proper help (Sayles 2007). Another point of stigmatization has been the fairly 
recent arrival of the PReP drug Truvada, which has been celebrated as a promising way to 
prevent transmission in higher risk demographics. Despite this immensely positive news, some 
high profile people in the LBGT community were quick to point out the promiscuity such a drug 
might allow (Calabrese 2015). Zachary Quinto commented, “…these drugs are not to be taken to 
increase our ability to have recreational sex”(Berlin 2014). While he is not wrong that some may 
see having a “magic pill” should allow just that,  he ignores the huge benefit for people, 
promiscuous and nonpromiscuous alike, in being able to have sex with others without the 
constant anxiety of possibly transmitting HIV (Calabrese 2015). 
However, stigma in HIV extends well beyond the United States and western Europe. In a 
2010 study by Turan, et al., it was noted that pregnant women in Kenya are less likely to get 
tested for HIV, keep up with antenatal prevention of HIV transmission, and seek help from 
maternity services when facing perceived stigma of HIV from their families and the community. 
Pregnant women are often the first members of their families tested for HIV, and in the event of 
a positive screening, can be seen as introducing the virus to their families. The study was able to 
confirm that a major predictor of HIV test acceptance was anticipated male partner approval or 
disapproval (Turan 2010). These results are important because PLHIV need to feel comfortable 
in seeking knowledge and help for their condition to prevent further spread of HIV, particularly 
in mother-to-child scenarios and in areas that have high transmission rates. 
 
A Survey of Stigma at UTK 
Based on these reports, a survey inquiring about both HIV awareness and stigma was 
performed across the University of Tennessee-Knoxville student and faculty population. 
Respondents were recruited through email and social media, and were kept completely 
anonymous. The survey, provided as a supplement, first asked five questions about HIV, which 
included what it was, how it was transmitted, and how or if it could be effectively treated. The 
next five questions asked respondents to rate on a zero-to-four scale different stigmatizing 
statements based on how much they agreed with them. The survey also asked respondents their 
gender, sexual orientation, age, and what department they were in at UT. All questions and 
recruitment practices were approved by the Institutional Review Board. The survey was 
discontinued after receiving 202 responses. Ninety percent of respondents were in the 18 to 24 
age range, with the other ten percent as old as 64. The sample was disproportionately female at 
67%. Eighty-two percent of respondents reported being straight, with 9% reporting as bisexual 
and only 5% gay. The others reported being asexual, other, or preferred not to respond. Each 
anonymous respondent was given a “stigma score” based on the combined numbers reported for 
all stigma statements. Results were analyzed using a linear regression, t-tests, and nonparametric 
Wilcox tests. 
Results showed that only 27% of respondents correctly answered every knowledge-based 
question. Ninety percent of respondents knew HIV was a virus, and 92% differentiated between 
HIV and AIDS. About 78% were aware antiretrovirals were used to treat HIV, but only 69% 
thought the 96% efficacy rate was true. Less than half correctly answered the question about 
transmission correctly. When a regression was done between stigma score and correctly 
answered questions (Figure 1), there was no significant trend. However, there were several 
significant differences in stigma scores for specific questions when compared between answering 
profiles for transmission methods. Because the question format allowed participants to check as 
many options as they thought correct, there were many possible answers and thus only two 
groups of respondents were considered: those who answered the question about transmission 
completely correctly, with no fewer and no more answers than required, and those who thought 
every transmission mode offered was correct. Not only were the overall stigma scores 
significantly different between these two groups (Figure 3), there were also significant 
differences in their agreement with statements about food handling by PLHIV (Figure 4), 
proximity to PLHIV (Figure 5), and HIV being a punishment for bad behavior (Figure 6). 
Despite these significant relationships, there was no difference in predicted self-shaming 
between the two answering profiles (Figure 2). It should be noted that other questions (e.g. 
treatment options, the difference between HIV and AIDS, efficacy of known treatments) did not 
elicit the same differences in stigma. 
 Figure 1: Overall stigma score versus number of overall correct answers. Stigma scores were calculated by 
adding degrees of agreement to each stigma statement together. There was no significant relationship 
between overall knowledge and apparent stigma when an F-test was performed (p=0.1411). 
 
  
Figure 2: Stigma score compared between two groups with different awareness of how HIV can be 
transmitted. The “all selected” group reported that all methods listed were possible ways of transmitting the 
virus: contact with infected blood, unprotected sex, contact with “infected” saliva, sharing needles, and 
mosquitoes. The “correct” group accurately reported all legitimate modes of transmission, no more and no 
less. Both a t-test and Wilcox test showed a significant difference in overall stigma between these two groups 
(p=0.0007). 
n=117 
p=0.0007 
  
Figure 3: Predicted internal stigma compared to understanding of transmission. Sample sizes are the same as 
those listed in Figure 3. A t-test showed the difference to be insignificant. 
 
  
Figure 4: Fear of contracting HIV from someone living with HIV handling one’s food compared between two 
groups with different levels of understanding of HIV transmission. Groups were the same as those stated in 
Figure 2. The stigma level associated with food preparation by PLHIV for each group was obtained from the 
stigma level reported on each survey, and then averaged. Sample sizes were the same as those used in Figure 
2. Both a t-test and a Wilcox test showed there was significantly more fear of transmission within the group 
selecting all transmission methods listed than within the group with only correct answers (p=0.0001). 
 
n=117 
p=0.21 
n=117 
p=0.0001 
  
Figure 5: Fear of being in the same confined area with someone living with HIV compared between two 
groups. The group selecting all modes of transmission listed showed significantly higher stigma scores than 
those with a more accurate knowledge of HIV transmission in both a t-test and a Wilcox test (p=0.0076). 
Sample sizes were the same as those in Figure 2. 
 
  
Figure 6: The average incidence of considering HIV a punishment for “bad behavior” between two groups. 
The group with more correct answers was less likely to stigmatize PLHIV than those seeing all modes of 
transmission listed as legitimate based on both a t-test and a Wilcox test (p=0.0180). Sample sizes were the 
same as those on Figure 2. However, it should be noted that few respondents fully agreed with the statement 
“HIV is a punishment for bad behavior.” Thus, this data should not be seen as confirming strong and 
widespread stigma, but rather as confirming a difference in two groups’ tendencies to not completely reject 
the statement. 
n=117 
p=0.0076 
n=117 
p=0.0180 
  Thus, the most pressing question surrounding these results is why one knowledge-based 
question would be more important in predicting stigma than others, particularly over those about 
the existence and efficacy of treatments. In addition, why would this trend not reflect in overall 
stigma? That someone who thinks they can get HIV through more than unprotected sex or blood 
exposure is fearful of contracting it in low risk situations makes sense. Even though it is based in 
inaccuracy, believing HIV is spread more easily than it actually is could foreseeably lead to more 
stigmatization, especially in the scope of food preparation or proximity. However, the same 
should arguably be true for those people who think there are no available treatments for HIV, but 
statistical analysis showed no significant difference between those who knew antiretrovirals are 
the chosen treatment for HIV and those who thought there were no available treatments. It is 
possible the survey design was flawed in that it asked about the efficacy of antiretrovirals after 
asking about what treatments were used, but did not bar respondents from editing  their previous 
answers. However, if it is assumed the indifference would hold either way, it might be possible 
that there is a larger fear associated with having to live with HIV than die of AIDS. If this is the 
case, it speaks volumes about society’s perception of HIV and acknowledged stigma surrounding 
HIV, as well as how little is actually known about the possibility of living a normal life with 
HIV. That two of the five questions were about treatment, which seemed to have no bearing on 
overall stigma, it is unsurprising that stigma could not be correlated with overall knowledge. 
That the only question correlating with stigma was about transmission suggests that HIV stigma 
is induced by fear of transmission, and that fear of getting HIV is borne out of an unclear 
understanding of the virus. However, more work would have to be done to confirm this 
relationship.  
Though this survey did give some insight about stigma at UT Knoxville and the 
relationship between knowledge and stigma, there were several limitations. The survey was kept 
fairly short to encourage participation. A longer survey could have provided more room for 
comparing knowledge and stigma. Even if the survey had been kept short, different questions 
may have afforded more stigma than the ones used. More demographic questions could have 
been added to establish better trends among minorities. Much of the existing literature about 
stigma and HIV has evolved out of its association with homosexual men, so it would be 
interesting to include a larger proportion in future study groups. Between this aspect and the fact 
that over 60% of respondents were female, it could be beneficial to do more targeted distribution 
to attain a more representative sample. This approach and any future endeavors might also 
benefit from having a larger sample than the 202 in this survey. Finally, the location could also 
affect the relationship between knowledge and stigma. According to a 2011 census, a higher 
proportion of HIV diagnoses were in southern states, which may have implications for how 
much is known or what might be stigmatized in the south (Reif 2014).  
 
 
Living with HIV 
Various studies have looked beyond the numbers to study the tangible, day-to-day effects 
of living with HIV in a world that stigmatizes it. In a 2007 study conducted in Los Angeles, 48 
HIV+ participants were put in groups and interviewed regarding their experiences with stigma. 
The study categorized these experiences as follows: innocence discourse, fear of contagion, 
disclosure, and negotiation of social contracts. “Innocence discourse” referred to the tendency for 
others to ask about how someone with HIV contracted it, and use that information to assign 
blame. Women described the difficulty in handling these questions, given how deeply personal it 
can be. If they are not the victims of some unfortunate event such as a rape or blood transfusion, 
they are presumed  to be promiscuous or drug-users. Homosexual men experience a similar 
stigma within the LGBT community, as shown by one man’s experience of overhearing other 
gay men’s disgust with HIV+ men. Despite many people assuming PLHIV inherited HIV 
through promiscuity or drug use, fear of contagion is another source of stigma, and what 
separates HIV from other chronic diseases. Though HIV is transmitted through unprotected sex 
or blood contact, people tend to harbor an irrational fear of contracting HIV through minimal 
contact. These reports are in line with the UT-Knoxville survey results showing that  people who 
have an incorrect understanding of transmission have higher levels of stigma. Fears such as these 
can limit how often PLHIV can enjoy platonic physical affection, sharing home-cooked meals, 
or even having normal experiences with HIV-discordant friends. However, it should be noted 
that successfully reestablishing these interactions with family members and friends can be 
meaningful to someone coming to terms with his or her status, and ultimately help them resume 
a less isolated existence (Sayles 2007).  
 Adding to possible isolation is the fear of disclosure common among PLHIV. Fear of 
disclosing a positive serostatus arises from fear of being stigmatized, labelled, or being seen only 
as someone with HIV. Such fear can creep into romantic relationships, career choices, and 
general approach to being a part of society. Thus, PLHIV without social support have reported 
avoiding intimacy to avoid disclosure, quitting jobs to avoid explaining inconsistent attendance 
due to health issues, or avoiding enjoyable activities to avoid having to explain their situation to 
others (Sayles 2007, Zhang 2016).  
Although studies have shown having social support helps outlook in PLHIV, stigma still 
affects those PLHIV who have maintained intimacy (Lee 2015, Rispel 2015). In the 2015 study 
from Rispel et al, researchers found 50 HIV-discordant couples distributed across three countries 
(Ukraine, Tanzania, and South Africa). Couples in the study gave testimonies of their 
experiences with the public and their own family members. Couples in Africa were labelled as 
being HIV-concordant and received pressure from their families to discontinue the relationship. 
Often, family members were confused by the couple’s claims that the HIV- partner could 
maintain his or her negative status, despite the existence and relative accessibility of HAART. 
One couple in Tanzania even reported being called a “walking corpse.” Couples in Ukraine 
experienced similar stigma, but also spoke more often of simply avoiding the subject of their 
discordant status out of fear of their families’ reactions, or public treatment of their families 
based on their proximity to HIV.  
Despite the fact that PLHIV can be limited by the perceived stigma in their daily lives, 
author Heather Boerner has captured today’s possibilities for PLHIV, specifically for those in 
HIV-discordant relationships trying to have children. She emphasizes what can actually be 
accomplished with the medications available today by telling the stories of two discordant 
couples in which the husband was HIV+. Both couples struggled to find safe ways to fulfill their 
dreams of having families. Though sperm washing for in vitro fertilization was a possibility 
before the potential of antiretrovirals was discovered, there was a long-time ban on donating and 
washing the sperm of HIV+ men, killing any hopes of safely creating a child of their own. Even 
after the ban was repealed, the process remained expensive with little guarantee it would actually 
work. However, a 2001 study in Uganda found that the transmission risk during unprotected sex 
was directly related to viral load. The lower the treatment, the less likely transmission would 
occur. In fact, the overall transmission risk per coital act was calculated being 0.1-0.2% (Gray 
2001). Not long after the Uganda study, Dr. Myron Cohen began studying the effects of early 
antiretroviral treatment on HIV-1 transmission. Though his findings were not published until 
2011, his research eventually confirmed that treating HIV as early as possible led to extremely 
low risks of transmission (Cohen 2011). Meanwhile, Boerner’s couples were scrambling for 
ways to conceive children. Both couples decided to take what at the time seemed like a huge 
risk—waiting for an ovulation cycle, testing both blood and semen for viral load, and carefully 
planning Truvada treatments for the HIV- negative wife prior to having unprotected sex (Boerner 
2014). Though the path was hardly easy for both couples, both were able to have healthy, HIV-
negative children and keep HIV-negative partners virus-free. While these stories involved two 
carefully controlled situations, they are still testament to what can be accomplished given the 
right opportunities, and are probably the most compelling evidence for HIV becoming less of a 
death sentence and more a chronic illness.  
 
Accessibility 
 While the fact that PLHIV have more possibilities is a tremendous and wonderful step in 
the right direction, the possibilities do not always become reality. The annual cost of 
antiretroviral treatment is staggering. Pascual gives the figure 6.5 billion USD per year to treat a 
mere 15 million PLHIV (Pascual 2014). Though programs like Medicaid and WHO guidelines to 
increase access can help offset these costs, someone with HIV, particularly those in the United 
States and Europe, can pay thousands of dollars per year for medications and healthcare (Koenig 
2015). A major contributor to the ingoing expense of antiretrovirals is the patents companies are 
allowed to hold for up to twenty years. During this time period, generics are not allowed to hit 
the market, which keeps costs higher for long periods of time. A few loopholes have been added 
to global policies in an attempt to soften the financial blow in less developed countries, such as 
allowing other companies to begin work on generic versions of medication before the patents 
expire and allowing companies in other countries to manufacture and sell a patent holder’s 
product for a certain cut of the profit (Pascual 2014). These measures have been somewhat 
effective in other countries, but those benefits have not extended to the United States, which 
remains one of the highest paying countries for pharmaceuticals(Koenig 2015). High costs can 
make it more difficult for people to obtain and adhere to their medications consistently, and the 
consequences of improper adherence to HIV medications can be serious. If medications are not 
taken as directed, it puts the patient at risk for not only increasing viral load above undetectable 
levels, but also allows a larger reservoir to form and increases the likelihood of viral resistance 
(Prevention 2016). Thus, if medications continue to be expensive with an ever increasing number 
of PLHIV, there will be a higher number of individuals needing something more advanced and 
even more expensive than the first line treatments available(Pascual 2014). All of this is to say 
that, while pharmaceutical companies must make a profit just like any other company, HIV is not 
a disease to be seen first and foremost as a business opportunity; rather, suppressing HIV needs 
to truly be the primary goal for companies worldwide.  
 Another important aspect of preventing HIV transmission is detecting it as soon as 
possible. The sooner a positive HIV status is discovered, the sooner medications can be 
prescribed, and the less viral load someone will incur. Even if someone recently diagnosed with 
HIV does not seek treatment right away for financial reasons or to evade the unpleasant side 
effects of antiretrovirals, being aware enough to avoid overly risky situations is important with or 
without medication. Therefore, access to affordable and discrete testing is pivotal. Options in the 
United States include walk-in clinics, blood testing labs, and in-home oral HIV test kits. At forty 
dollars, test kits are less expensive than going to a clinic or lab and are cheap compared to the 
overall cost of being diagnosed with HIV. However, forty dollars becomes a steep price for low 
income demographics, particularly adolescents. In a recent study focusing on low-income 
adolescents in Chicago and San Francisco, teens were asked about their opinions on accessing 
home testing kits. Even though they can be bought at drug stores, the forty dollar price tag was a 
drawback, as well as the likelihood of being stigmatized or recognized while purchasing such a 
kit. This may be especially problematic in smaller, less urban communities where faces are more 
familiar and getting to a simple drug store may be more difficult. The investigators proposed a 
mailing service or a vending system of sorts, in which more sensitive tests could be dispensed 
without necessitating human interaction. Making these tests more universally available through 
nonprofit organizations would also reduce the cost to about $11.00, just over a fourth of the 
normal cost(Catania 2015). These same strategies may benefit women in the same situation as 
those discussed in Turan’s study in Kenya. Their decision to get tested was heavily based on 
their partner’s reaction to a positive HIV status. Perhaps offering a more discrete testing option 
that could be performed without a clinic would alleviate those fears enough to increase 
willingness to undergo an HIV test (Turan 2010).  
 
Conclusions 
 Since the 1980s, HIV has become much more a part of the global vocabulary. Since then, 
we have poured resources into studying the virus itself, how to keep it at bay, and how to destroy 
the disease entirely. Even though we are far from actually curing HIV, we have made excellent 
progress toward being able to coexist with it. By and large, it is access to care and perceived 
stigma standing in the way of PLHIV living normal and happy lives, not so much what we have 
or have not accomplished in the laboratory. The anonymous couples Heather Boerner sought out 
are hopefully only the beginning of the successes for PLHIV. In the end, it seems PLHIV do not 
need a cure to achieve the same basic needs as those without HIV. And yet, the stigma still 
exists. Many studies, especially those from Rispel and Sayles, point toward 
compartmentalization and avoidance as a way of coping with HIV. We as a society seem to do 
the same, as common “solutions” to achieving greater testing and treatment success lies in 
discretion and laying low (Catania 2015). Given the difficulties in completely eradicating viruses 
overall, we need to be able to talk about HIV as an issue instead of sweeping it under a rug, 
hoping it will go away. The facts about HIV, particularly those regarding transmission and how 
to access treatment, need to be spread far and wide (Zhang 2016).  
 Though HIV has inspired a huge amount of global effort, it is not unique in its proclivity 
for attracting stigma. Sexually transmitted infections (STIs) have seen a similar development of 
stigma, and avoidance of diagnosis and treatment due to that stigma (Morris 2014). Perhaps the 
largest separation between HIV and other STIs is the potential of an early death and little 
progress on a true cure. Others can be treated with antibiotics, or at least are not liable to destroy 
an immune system over time. And yet there is still significant stigma surrounding these lesser 
diseases. Perhaps the label “sexually transmitted” has become a call for stigma, despite the 
constant presence of sex and sexuality in our society. Perhaps this means that eradicating HIV-
related stigma is farther away than eradicating HIV itself.  
 As far as research goes, seeing people emulate work like the Uganda study or Dr. 
Cohen’s  would be a breath of fresh air, simply because they worked with what was available to 
move mountains for HIV-discordant couples in the here and now instead of calling it impossible, 
or chasing something that could be lightyears away. This is not to say progress is bad or 
wasteful, but it is a reminder that progress can come in many forms. Taking steps such as these 
to giving PLHIV the same lifestyle options as those without could go far in destigmatizing HIV. 
By giving PLHIV an identity other than “PLHIV,” maybe we can start seeing them as more than 
one decision, one life event, or one way to exist. The next step is making those scenarios outlined 
by Boerner possible worldwide by providing cheaper medications faster, and continued 
establishment of health clinics. That PLHIV can accomplish all the things they could without 
HIV may not change stigma right away, or even in a lifetime, but actions can speak louder than 
words.  
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Supplement: HIV Awareness and Stigma Survey 
 
1. What is HIV? 
a. Cancer 
b. A virus 
c. A genetic disorder 
d. Bacterial infection 
e. A parasite 
 
2. Which of the following are ways HIV can be transmitted? 
(Check all that apply) 
- Contact with HIV-positive blood 
- Unprotected sex 
- Contact with saliva from someone with HIV 
- Sharing needles 
- Mosquitoes  
 
3. How is HIV currently treated? 
a. Antibiotics 
b. Chemotherapy 
c. Antiretrovirals 
d. There are no known treatments for HIV 
 
4. True or False: Antiretrovirals are approximately 96% effective in preventing HIV 
transmission when taken properly.  
 
5. True or False: HIV is the same thing as AIDS. 
 
6. On a scale of 0 (strongly disagree) to 4 (strongly agree), how much would you agree with 
this statement? 
 
If one of my family members contracted HIV, I would be ashamed. 
 
0-strongly disagree 
1-disagree 
2-neutral 
3-agree 
4-strongly agree 
 
7. On a scale of 0 (strongly disagree) to 4 (strongly agree), how much would you agree with 
this statement? 
 
If I contracted HIV, I would be ashamed of myself. 
 
0-strongly disagree 
1-disagree 
2-neutral 
3-agree 
4-strongly agree 
 
8. On a scale of 0 (strongly disagree) to 4 (strongly agree), how much would you agree with 
this statement? 
 
If someone living with HIV were to prepare my food, I would fear contracting HIV. 
 
0-strongly disagree 
1-disagree 
2-neutral 
3-agree 
4-strongly agree 
 
9. On a scale of 0 (strongly disagree) to 4 (strongly agree), how much would you agree with 
this statement? 
 
If I were sitting in an enclosed space with someone with HIV, I would fear contracting HIV 
myself. 
 
0-strongly disagree 
1-disagree 
2-neutral 
3-agree 
4-strongly agree 
 
10. On a scale of 0 (strongly disagree) to 4 (strongly agree), how much would you agree with 
this statement? 
 
HIV is a punishment for bad behavior. 
 
0-strongly disagree 
1-disagree 
2-neutral 
3-agree 
4-strongly agree 
 
11. How old are you? 
 
12. What is your gender? 
 
13. What is your sexual orientation? 
 
14.       If you are student or faculty, what department are you in? 
Role in Project 
 
The Principal Investigator, Renee Adamec, conducted a survey of the University of Tennessee-
Knoxville’s students and faculty to try to correlate knowledge and stigma surrounding HIV. She 
also reviewed scientific literature to inspire the survey, explain results, and suggest a new 
perspective on HIV. 
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